Pharming (PHAR) Change in Receivables (2019 - 2026)

Pharming (PHAR) has 7 years of Change in Receivables data on file, last reported at -$3.4 million in Q4 2025.

• Quarterly Change in Receivables rose 50.54% year-over-year to -$3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6.8 million (up 77.13% YoY) and the FY2025 annual result came in at -$3.4 million, up 50.54% from the prior year.
• Change in Receivables slipped to -$3.4 million in Q4 2025, from $1.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $4.7 million in Q3 2021 to a low of -$18.5 million in Q4 2023.
• A 5-year average of -$2.1 million and a median of $49000.0 in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2021 — Change in Receivables soared 40409.31% — and 2023, when it slumped 1168.06%.
• Tracing PHAR's Change in Receivables over 5 years: stood at $3.0 million in 2021, then slumped by 149.38% to -$1.5 million in 2022, then tumbled by 1168.06% to -$18.5 million in 2023, then soared by 63.41% to -$6.8 million in 2024, then jumped by 50.54% to -$3.4 million in 2025.
• The last three Change in Receivables figures came in at -$3.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.8 million (Q1 2025), per Business Quant data.